View Older Stories View More Recent Stories

Mar 8, 2021 08:08AM Lineage Cell Therapeutics (LCTX) Raises $35.9 Million From Sales of Marketable Securities Holdings and an At-the-Market Equity Offering
Mar 8, 2021 08:00AM Lineage Cell Therapeutics Raises $35.9 Million From Sales of Marketable Securities Holdings and an At-the-Market Equity Offering
Nov 12, 2019 04:05PM Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
Feb 14, 2019 08:00AM BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias
Jan 30, 2019 08:09AM BioTime (BTX) Confirms Affiliate Company OncoCyte (OCX) Reported Successful Results With DetermaVu Diagnostic Test for Lung Cancer
Nov 8, 2018 06:35AM BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company
Nov 8, 2018 06:30AM BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update
Nov 6, 2018 04:30PM BioTime Announces Update to Third Quarter 2018 Financial Results Conference Call
Nov 5, 2018 08:00AM BioTime Receives Second Installment Payment of $10.8 Million From Juvenescence Ltd.
Oct 30, 2018 08:00AM BioTime to Report Third Quarter 2018 Financial Results on November 8th, 2018
Oct 29, 2018 08:00AM BioTime Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting
Oct 25, 2018 08:00AM BioTime Announces November 16, 2018 Record Date and November 28, 2018 Distribution Date for the Distribution of Age-X Therapeutics Shares
Oct 22, 2018 08:00AM BioTime to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 28th
Sep 27, 2018 07:00AM BioTime to Present at the Upcoming Ladenburg Thalmann and MicroCap Conferences
Sep 25, 2018 07:00AM BioTime to Participate on Industry Perspectives Roundtable at NEI Audacious Goals in Regenerative Medicine Workshop: Pathways for Retinal Cell Replacement Therapies
Sep 21, 2018 07:00AM BioTime Warrants to Expire on October 1, 2018
Sep 18, 2018 07:00AM BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer
Sep 18, 2018 07:00AM BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer
Sep 17, 2018 01:00AM BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Shareholders
Sep 4, 2018 06:55AM BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence
Aug 28, 2018 07:00AM BioTime’s CEO Adi Mohanty and CFO Russell Skibsted to Participate in Upcoming Panel and Conferences
Aug 16, 2018 08:00AM AgeX Therapeutics Acquires Technology to Regulate Immune Tolerance
Aug 16, 2018 07:00AM BioTime to Present Data at the Military Health System Research Symposium
Aug 2, 2018 04:05PM BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
Aug 2, 2018 08:00AM BioTime to Receive $43 Million From Juvenescence
Aug 2, 2018 07:00AM BioTime Announces the Start of an Investigator Initiated Study of Premvia™ Designed and Conducted by Dr. Gordon H. Sasaki
Aug 1, 2018 06:12PM BioTime Announces Distribution Ratio for Distribution of AgeX Therapeutics Shares
Jul 25, 2018 07:00AM Data from BioTime’s OpRegen® Program to Be Presented at AAO 2018
Jul 23, 2018 07:00AM BioTime to Announce Second Quarter 2018 Results on August 2, 2018
Jul 11, 2018 07:00AM AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research, July 12 in New York City
Jul 10, 2018 07:00AM BioTime Announces July 31, 2018 Record Date for the Distribution of AgeX Therapeutics Shares
Jun 29, 2018 07:00AM BioTime Awarded Grant From the NIH
Jun 25, 2018 07:00AM BioTime Licenses GMP Cell Line to Goliver Therapeutics
Jun 11, 2018 07:00AM AgeX Therapeutics Closes on $5 Million Strategic Investment From Juvenescence
Jun 8, 2018 07:00AM BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares
Jun 5, 2018 07:00AM AgeX Therapeutics Appoints John F. Mauldin to Board of Directors
May 30, 2018 07:00AM BioTime to Present at the 8th Annual LD Micro Invitational
May 29, 2018 07:05AM BioTime (BTX) Secures $1.9M Grant for Continued Development of OpRegen for Dry-AMD
May 29, 2018 07:00AM BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
May 24, 2018 07:00AM BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites
May 17, 2018 07:00AM AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London
May 10, 2018 04:05PM BioTime Reports First Quarter Results and Recent Corporate Accomplishments
May 2, 2018 07:00AM AgeX Announces NIH Grant Award
May 1, 2018 08:00AM BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO
Apr 26, 2018 07:00AM BioTime to Announce First Quarter 2018 Results on May 10, 2018
Apr 16, 2018 07:00AM Data from BioTime’s OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018
Apr 9, 2018 08:00AM Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit
Mar 27, 2018 07:09AM BioTime (BTX) to Receive up to $3.5 million in Cash from Sale of Ascendance Biotechnology
Mar 27, 2018 07:00AM BioTime Announces Cash Sale of Ascendance Biotechnology
Mar 15, 2018 04:05PM BioTime Reports Fourth Quarter and Fiscal 2017 Results
View More Recent Stories View Older Stories